Please use this identifier to cite or link to this item: https://doi.org/10.3390/cells10123348
DC FieldValue
dc.titlePre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy
dc.contributor.authorMirzaei, Sepideh
dc.contributor.authorGholami, Mohammad Hossein
dc.contributor.authorAng, Hui Li
dc.contributor.authorHashemi, Farid
dc.contributor.authorZarrabi, Ali
dc.contributor.authorZabolian, Amirhossein
dc.contributor.authorHushmandi, Kiavash
dc.contributor.authorDelfi, Masoud
dc.contributor.authorKhan, Haroon
dc.contributor.authorAshrafizadeh, Milad
dc.contributor.authorSethi, Gautam
dc.contributor.authorKumar, Alan Prem
dc.date.accessioned2023-02-14T03:00:04Z
dc.date.available2023-02-14T03:00:04Z
dc.date.issued2021-12-01
dc.identifier.citationMirzaei, Sepideh, Gholami, Mohammad Hossein, Ang, Hui Li, Hashemi, Farid, Zarrabi, Ali, Zabolian, Amirhossein, Hushmandi, Kiavash, Delfi, Masoud, Khan, Haroon, Ashrafizadeh, Milad, Sethi, Gautam, Kumar, Alan Prem (2021-12-01). Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy. CELLS 10 (12). ScholarBank@NUS Repository. https://doi.org/10.3390/cells10123348
dc.identifier.issn2073-4409
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/237216
dc.description.abstractPancreatic cancer (PC) is one of the leading causes of death and is the fourth most malignant tumor in men. The epigenetic and genetic alterations appear to be responsible for development of PC. Small interfering RNA (siRNA) is a powerful genetic tool that can bind to its target and reduces expression level of a specific gene. The various critical genes involved in PC progression can be effectively targeted using diverse siRNAs. Moreover, siRNAs can enhance efficacy of chemotherapy and radiotherapy in inhibiting PC progression. However, siRNAs suffer from different off target effects and their degradation by enzymes in serum can diminish their potential in gene silencing. Loading siRNAs on nanoparticles can effectively protect them against degradation and can inhibit off target actions by facilitating targeted delivery. This leads to enhanced efficacy of siRNAs in PC therapy. Moreover, different kinds of nanoparticles such as polymeric nanoparticles, lipid nanoparticles and metal nanostructures have been applied for optimal delivery of siRNAs that are discussed in this article. This review also reveals that how naked siRNAs and their delivery systems can be exploited in treatment of PC and as siRNAs are currently being applied in clinical trials, significant progress can be made by translating the current findings into the clinical settings.
dc.language.isoen
dc.publisherMDPI
dc.sourceElements
dc.subjectScience & Technology
dc.subjectLife Sciences & Biomedicine
dc.subjectCell Biology
dc.subjectpancreatic cancer
dc.subjectsmall interfering RNA (siRNA)
dc.subjectdrug resistance
dc.subjectco-delivery
dc.subjectnanoparticles
dc.subjectMESOPOROUS SILICA NANOPARTICLES
dc.subjectGROWTH-FACTOR RECEPTOR
dc.subjectPOLYMER HYBRID NANOPARTICLES
dc.subjectIRON-OXIDE NANOPARTICLES
dc.subjectRIG-I ACTIVATION
dc.subjectCELL LUNG-CANCER
dc.subjectHISTONE-DEACETYLASE
dc.subjectRIBONUCLEOTIDE REDUCTASE
dc.subjectGOLD NANOPARTICLES
dc.subjectDRUG-DELIVERY
dc.typeReview
dc.date.updated2023-02-13T06:33:01Z
dc.contributor.departmentPHARMACOLOGY
dc.description.doi10.3390/cells10123348
dc.description.sourcetitleCELLS
dc.description.volume10
dc.description.issue12
dc.published.statePublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Thera.pdf3.12 MBAdobe PDF

OPEN

PublishedView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.